C12Y 207/1101
Ikappab kinase
Official title: IkappaB kinase (2.7.11.10)
C12Y207/1101 (Ikappab kinase) appears on 13 US grants and 24 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 24
- Assignees
- 20
- Inventors
- 45
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 3 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 3 |
| 2016 | 0 | 1 |
| 2017 | 2 | 0 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 0 | 0 |
| 2021 | 2 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Altering inflammatory states of immune cells in vivo by modulating cellular activation states17 Mar 2026US 12,576,131 B2Fred Hutchinson Cancer Center
- MEl'hods and means for diagnosing spondylarthritis using autoantibody markers14 Dec 2021US 11,199,549 B2Medizinische Hochschule Hannover
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides16 Mar 2021US 10,947,539 B2Portage Pharmaceuticals Ltd.
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides28 May 2019US 10,301,629 B2Portage Pharmaceuticals Ltd.
- Methods and means for diagnosing spondylarthritis using autoantibody markers13 Mar 2018US 9,915,664 B2Medizinishce Hochschule Hannover
- Altering inflammatory states of immune cells in vivo by modulating cellular activation states4 Jun 2026US 2026/0151455 A1Fred Hutchinson Cancer Center
- Genetically engineered mice models for multiple myeloma29 Jan 2026US 2026/0026479 A1FundacióN Para La InvestigacióN MéDica Aplicada
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides17 Jun 2021US 2021/0180069 A1PPL (BVI) Limited
- Altering inflammatory states of immune cells in vivo by modulating cellular activation states18 Feb 2021US 2021/0046156 A1Fred Hutchinson Cancer Research Cente
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides23 May 2019US 2019/0153450 A1Portage Pharmaceuticals Ltd.
Most cited
By later US patents
- IkB kinase, subunits thereof, and methods of using same15US 6,242,253 B1The Regents of the University of California · 2001
- IKB kinase and methods of using same9US 6,268,194 B1The Regents of the University of California · 2001
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides6US 10,301,629 B2Portage Pharmaceuticals Ltd. · 2019
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides1US 10,947,539 B2Portage Pharmaceuticals Ltd. · 2021
- IκB kinase, subunits thereof, and methods of using same1US 6,689,575 B2The Regents of the University of California · 2004